



The CNGB is funded by the CCP, WHO, pharma, and Bill Gates. The CNGB in Shenzhen, CN is the world's largest DNA databank. BGI-operated CNGB is an official partner of the GISAID initiative.



**China National Gene Bank (CNGB Overview)**

- Non-profit organization
- Public Private Partnership (PPP)
- Jointed funded by State Government, Shenzhen Municipal government and BGI
- Operated by BGI Research

**Missions:**

- To act as a platform for integrating genetic resources and capabilities
- To lead the innovation, exploration and testing of new genomics technologies
- To support the development of the life sciences and bio-economy in China
- To maintain international competitiveness and influence in global genomics community



**GISAID EpiCov™ Database**

Until 2021-09-09 21:11:34 CST, the total number of entries is 3,379,134.

China National GeneBank Database (CNGBdb) is an official partner of the GISAID initiative. It provides access to EpiCov and features the most complete collection of nCoV-19 genome sequences along with related clinical and epidemiological data. With the data from this database, scientific researchers can construct a viral phylogenetic tree to reveal the characteristics of the pathogen, and provide effective references for the study and analysis of the evolutionary source and pathological mechanism of the novel coronavirus.

**United States of America**

The United States Department of Health and Human Services, through its Centers for Disease Control and Prevention (CDC) is the first government to support the creation of the GISAID Initiative, by providing since 2007 technical guidance, public funding as well as substantial in-kind contributions for the ongoing development of the EpiFlu™ database application and GISAID's educational programs.



Americans get COVID-19 data from the CDC. The CDC gets COVID-19 data from the NIH and GISAID. The NIH and GISAID both get COVID-19 data from the CNGB.

**Public genome repositories for SARS-CoV-2**

**COVID-19 Genomic Epidemiology Toolkit: Module 3.5**

Michael Weigand, PhD  
Bioinformatics  
Centers for Disease Control and Prevention

[cdc.gov/coronavirus](https://www.cdc.gov/coronavirus)

**Rationale for sequencing SARS-CoV-2**

- State/local level
  - Supplement control efforts
  - Better understand epidemiology
- National level
  - Strain surveillance
  - Guide diagnostics, vaccine, and therapeutic development
- Collecting sequences in public databases strengthens both
  - Submission should be included in any SARS-CoV-2 sequencing workflow
  - More valuable if clinical, epidemiological metadata included

**Public repositories for SARS-CoV-2 genomic data**

- GISAID** (Global Initiative on Sharing All Influenza Data)
  - Facilitates rapid sharing of data from influenza (EpiFlu) and SARS-CoV-2 (EpiCoV)
- NCBI/NLM** (National Center for Biotechnology Information)
  - US National Institutes of Health (NIH)
  - GenBank®, Sequence Read Archive (SRA), PubMed, BLAST®, etc.
  - Facilitates public access and rapid sharing of SARS-CoV-2 sequences
  - Integrates SARS-CoV-2 data with literature (PubMed/PMC) and the BLAST® databases

Different submission standards, organizations, primary uses  
Both provide searchable collections of genomic data and epidemiologic metadata.



**Summary**

- Public repositories facilitate organized, open data sharing
- Maximize utility of SARS-CoV-2 genome sequence data
  - Support resources like public Nextstrain builds
  - Query, download sequences to supplement local analyses or investigation
- Pay it forward
  - Submitting your data to both repositories can help others!
  - Better with clinical, epidemiological metadata (PHA4GE)

For more information, contact CDC  
1-800-CDC-INFO (232-4630)  
TTY: 1-888-232-4344 [www.cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

In 2016, the University of Washington in Seattle and Washington State University both signed MOUs with BGI-Group to advance biomedical research in China.



**WASHINGTON STATE UNIVERSITY**

**WSU Signs MOU with BGI**

SHENZHEN, China – Washington State University and BGI signed a Memorandum of Understanding regarding basic and applied research in agriculture, Wednesday. The MOU was signed by WSU Vice President for International Programs Asif Chaudhry and Dr. Huanming Yang, Chairman of BGI.

**BGI** myBGI Change region

- In 2016, BGI expanded its presence in North America with a new office in Seattle, supporting partnerships with universities, companies and health-related organizations, including the Bill & Melinda Gates Foundation and the University of Washington. In 2017 BGI opened a Global Innovation Center in Seattle and San Jose to build an ecosystem of innovation in the two high-technology clusters and promote cross-sector collaboration.



**BGI Genomics at a Glance**

**Who We Are**

BGI (BGI Genomics and its sister entities under BGI Group) is the world's largest genomics organization. Its commercial subsidiary, BGI Genomics, provides a wide range of genomic research services, genetic tests and IVF products across more than 100 countries. BGI, which was founded in 1999 as a research organization to support the Human Genome Project, focuses on research, diagnostics and applications in the health care, pharmaceutical, and environmental fields. BGI has a proven track record of leading innovative, multi-omics research and the company operates 25 innovation centers to accelerate industry transfer of genomic technologies.

**100+** countries and solutions are available in 100+ countries

**391+** peer-reviewed papers published in the world's leading journals, including Nature, Science, Cell, and others, and the New England Journal of Medicine.

**7,000+** BGI researchers worldwide

**BGI U.S. Collaborations**

These collaborations help to better serve the research and genomics community

- Children's Hospital of Philadelphia (CHOP) joins genome center, 1,000 Rare Disease Project, Clinical WES for rare disease diagnosis
- Smithsonian Institution, increased collaboration in environmental and biodiversity science, developed advanced research in Biodiversity Genomics
- Natera, commercialized Signatera™ oncology test for Molecular Residual Disease (MRD) assessment and recurrence monitoring in China
- Bill & Melinda Gates Foundation, worked with 37 world-leading universities and organizations, 22 research projects on various subjects
- Fred Hutchinson Cancer Research Center, research collaboration in cancer genomics, immunology and infectious disease studies
- Merck, establish strategic collaboration focused on biomarkers and genomic technologies

**BGI Key Milestones in Infectious Disease Diagnostics**

- 2003: BGI's first sequencing and diagnostic kit on SARS virus
- 2004: First sequencing and diagnostic kit on SARS virus
- 2011: First sequencing and diagnostic kit on H5N1 avian influenza virus
- 2014: First sequencing and diagnostic kit on H7N9 avian influenza virus
- 2020: BGI's first sequencing and diagnostic kit on SARS-CoV-2
- 2020: BGI's first sequencing and diagnostic kit on SARS-CoV-2

**BGI AMERICAS CORP**  
One Broadway, 3rd Floor  
Cambridge, MA 02142, USA  
(617) 552-2766  
[bgi-america.com](https://www.bgi-america.com)  
Search: BGIUSA

In January of 2017, the Gates family and the Bill and Melinda Gates Foundation had already donated more than 1.25 billion dollars to the University of Washington in Seattle.

**\$1.25 billion from the billionaires in the backyard**

Over the past two decades, the Gates family and the Bill & Melinda Gates Foundation have donated \$1.25 billion to the University of Washington. That includes this week's 10-year, \$279 million grant – the largest single gift in UW history, and among the largest to any U.S. university. Here are the Gates Foundation's grants to the UW that exceeded \$10 million.

GRANT TITLE	START DATE	AMOUNT
Institute for Health Metrics and Evaluation (IHME)	11/23/18	\$279,305,473
Population Health Building	10/14/16	\$10,000,000
IHME creation	5/1/07	\$10,228,184
HIV prevention research	7/3/07	\$9,284,441
Genome Sciences capital campaign	6/27/03	\$9,000,000
Hepatitis B research	5/2/03	\$8,847,395
Disease Control Priorities Network	4/1/09	\$4,790,441
William H. Gates Law Scholarship Program	12/5/05	\$4,376,939
Geographical analysis of disease	10/14/15	\$4,043,011
IHME Global Center of Disease Study	7/5/13	\$3,923,046
Creation of Global Health Department	11/1/05	\$3,000,000
Global Libraries legacy program	6/8/16	\$1,918,283
Research on rapid diagnostics	7/1/05	\$1,442,325
Mary Gates Scholarship	3/27/95	\$1,000,000
IHME collaborative research	7/1/08	\$1,429,296
Global Innovation Exchange	10/21/15	\$1,000,000

Source: The Bill & Melinda Gates Foundation  
KELLY SHEA / THE SEATTLE TIMES

**BGI Group** @TheBGIGroup

Tadataka Yamada, (ex Bill & Melinda Gates Foundation & GSK) Joins BGI [genomics.cn/en/news/show\\_n...](https://genomics.cn/en/news/show_n...)

7:19 PM · Apr 25, 2016 · Twitter Web Client



**EXC: NIH Director & Fauci Boss Advises Chinese Military Proxy-Linked Group Working Alongside COVID-19 Gene Storage Firm.**



The CNGB partnered with GISAID on March 17, 2020 9 days later, the FDA issued an Emergency Authorization in the U.S. for the SARS-2019-nCoV PCR Kits built by BGI-Group.

**Chinese, intl. platforms to start virus data sharing**

From: Shenzhen Daily  
Updated: 2020-03-17 09:03

Shenzhen-based China National GeneBank (CNGB) has officially established a strategic partnership with the Global Initiative on Sharing All Influenza Data (GISAID) to promote the international sharing of gene data on viruses associated with respiratory infectious diseases yesterday.

China National GeneBank Database (CNGBdb), a unified platform for biological big data sharing and application service, is the first Chinese platform to be authorized by GISAID, according to information released by CNGB.

The collaboration allows researchers in China to access influenza virus data with novel analysis tools and also marks an important milestone for the contributions made by Chinese research institutes to the global sharing of influenza virus data. CNGBdb will act as a fast channel for the publication of domestic scientific and technological research on the basis of open data sharing and respect for all rights and interests upheld by GISAID, according to CNGB.

COVID-19, which has spread across the globe and killed more than 6,000 people, is now officially recognized by the World Health Organization as a pandemic. Information suggests that sharing virus data associated with respiratory infectious diseases globally is essential to protecting human health, especially amid a virus outbreak. Sharing this information faster can thus provide a better basis for epidemic risk evaluation and drafting preventative measures.

Founded in 2008, GISAID is said to be the world's biggest influenza virus data platform, with sources provided by 14,000 researchers and 1,500 institutions from around the world.

Approved by the Chinese Government in 2011, CNGB, China's first national integrated gene bank operated by BGI-Research, has been playing a key role in the fight against COVID-19 in Guangdong Province.

As one in a network of emergency COVID-19 testing laboratories established by BGI throughout the country, Shenzhen Daipeng Hui-Yan (Piercing Eyes) Lab was put into service Feb. 15 and has provided over 80,000 virus tests to Shenzhen and surrounding cities. The lab has an output capacity of up to 10,000 sample tests per day, said CNGB.

Contact Us | Site Map  
Copyright © 2020 BGI-Group  
ICP Registration Number: 440302020000000  
Police Registration Number: 440302020000000  
Business License: 440302020000000  
Sponsored by: General Office of Shenzhen Municipal People's Government  
Technical Support: Shenzhen Big Data Resources Management Center  
Without written authorization from Shenzhen Municipal People's Government, the content of this site shall not be reproduced or used in any form.

**FDA U.S. FOOD & DRUG ADMINISTRATION**

January 28, 2021

Bethany Hills, Partner  
Morrison & Foerster  
Representing: BGI Genomics Co. Ltd.  
250 West 55th Street,  
New York, NY 10019

Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2

Device: EUA200034  
Company: **BGI Genomics Co. Ltd.**  
Indications: Qualitative detection of SARS-CoV-2 nucleic acids in throat (oropharyngeal) swabs, nasopharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal mucus, nasal aspirates and bronchoalveolar lavage fluid (BALF) from individuals who are suspected of COVID-19 by their healthcare provider. Emergency use of this test is limited to authorized laboratories.


Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC 13203, that meet requirements to perform high complexity tests.

Dear Ms. Hills:

On March 26, 2020, based on your request, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of your Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV for the qualitative detection of SARS-CoV-2 nucleic acids in throat swabs and bronchoalveolar lavage fluid (BALF) from individuals suspected of COVID-19 by their healthcare provider, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360aa-3).<sup>1</sup> Based on your request, FDA has also granted updates to the authorized labeling on April 24, 2020.<sup>2</sup>

<sup>1</sup> For ease of reference, this letter will use the terms "you" and related terms to refer to the BGI Genomics Co. Ltd.  
<sup>2</sup> In this case, testing was limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 13203, to perform high complexity tests.  
<sup>3</sup> On April 24, 2020, your request was granted to update the Instructions for Use of your product to: (1) revise the name of the device to Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2; (2) add the Merck High-Density Nucleic Acid Extraction Kit for specimen processing, including the option for automation using the MDP-960RES High-Density Automated Sample Processing System; (3) add additional Real-Time PCR systems, Applied Biosystems 7500 Fast Real-Time PCR System, QuantStudio-1 Real-Time PCR System and the LightCycler 480 System; (4) add nasopharyngeal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal mucus, nasal aspirates to the intended use and associated limitation; (5) correct grammatical and typographical errors and (6)

In July of 2021, it was reported that BGI-Group had collected the DNA of more than 8.4 million pregnant women from around the world through a pre-natal test kit



Test results can also be used for research and to improve the diagnosis and treatment of genetic diseases. I consent to the storage and use of my anonymous test results in a statistical database for scientific purposes and to facilitate and improve the diagnosis of genetic changes and diseases in other patients. I understand that I will remain anonymous and identifiable during data analysis and that any personal information will be retained non-personal information to use BGI research to use it for any reports or publications. I consent that the results stored in the database are being provided to physicians, scientists and researchers.



**CORONAVIRUS**  
BGI Group Providing Worldwide COVID-19 Tests Exposed As Front For Chinese Military


**SOCIAL ISSUES**  
BGI's Goal: Customize Humans and Synthesize Biochemical Weapons



Joe Biden (whose son Hunter has worked with BGI executives) rolled out a \$200M CDC genome sequencing investment in Feb. 2021 - U.S. delta variant data from GISAID exploded soon after

**Why the US may not see the next dangerous coronavirus variant coming**  
The US lags behind on yet another tool to end the pandemic: viral genetic sequencing.

**WH.GOV**  
Rapidly Increase Virus Genome Sequencing. The Centers for Disease Control and Prevention (CDC) will invest nearly \$200 million to identify, track, and mitigate emerging strains of SARS-CoV-2 through genome sequencing. This down payment will increase CDC's sequencing more than threefold from about 7,000 samples per week to approximately 25,000.



**GISAID Country Submission Count**

Country	Total #Delta GK (B.1.617.2+AY*)	#Delta GK (B.1.617.2+AY*) in past 4 weeks	%Delta GK (B.1.617.2+AY*) in past 4 weeks
United Kingdom	374,153	75,483	99.9
USA	256,903	37,743	93.2
Denmark	43,540	15,172	99.9
Turkey	38,559	26,482	83.7
Germany	35,743	17,485	99.5
France	27,925	602	90.9
India	22,027	44	67.7
Sweden	17,869	4,424	99.9
Netherlands	15,200	1,571	99.4
Italy	14,390	2,583	98.6

similar. Thus, no performance impact was observed with this mismatch. Current presence of this mutation can be found in Table 8, from the in-silico analysis performed on June 6, 2021.


In summary, the assessment of homology between available sequences of SARS-CoV-2 as of June 6, 2021 and the CDC panel assay primers and probes shows that the risk of significant loss in reactivity and false negative results is very low due to the absence of significant numbers of mismatches. The design of the primers and probes, with melting temperatures of 56°C and an annealing temperature of 55°C, can tolerate up to two mismatches depending on location without significant loss in assay sensitivity.

**Table 8. In-Silico Industry Analysis of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel Among 851,810 Global Genome Sequences and 295,775 U.S. Sequences Submitted to GISAID within Three Months of June 6, 2021.**

Primer/probe	4	5	6	7	8	9	10	11	12
Location (nt)	4	5	6	7	8	9	10	11	12
Nucleotide	C/T	C/T	G/T	T/C	C/T	C/T	C/A	G/A	G/A
Mismatch No. (global sequences)	889	1,723	2,362	1051	13,621	1383	2,004	959	959
Mismatch Frequency (% global sequences)	0.12	0.21	0.28	0.13	1.64	0.19	0.24	0.12	0.12
Mismatch No. (U.S. sequences)	385	873	231	1,028	8,997	569	1,273	377	377
Mismatch Frequency (% U.S. sequences)	0.10	0.30	0.08	0.34	3.04	0.19	0.41	0.13	0.13

From: [janeyu@bgi.com](mailto:janeyu@bgi.com)  
Date: January 24, 2019 at 11:17 PM  
Subject: [Redacted]


Bill Gates, the Biden-Harris administration, and China are funding GISAID so BGI can store, analyze, and track America's DNA to control the pandemic narrative and enforce their agenda



The pandemic represents a rare but narrow window of opportunity to reflect, reimagine, and reset our world."

Professor Klaus Schwab  
Founder and Executive Chairman, World Economic Forum

Under Trump, in July 2020, the U.S. Department of Commerce sanctioned two Chinese subsidiaries of BGI for their repression and abusive DNA collection of Uyghurs



A Million People Are Jailed at China's Gulags. I Managed to Escape. Here's What Really Goes on Inside



China Uses DNA to Map Faces, With Help From the West  
Beijing's pursuit of control over a Muslim ethnic group pushes the rules of science and raises questions about consent.

**The New York Times**  
China Uses DNA to Track Its People, With the Help of American Expertise  
The Chinese authorities turned to a Massachusetts company and a prominent Yale researcher as they built an enormous system of surveillance and control.

"Our patience is wearing thin..."  
Because delta variant data...  
"The unvaccinated minority can cause a lot of damage, and they are..."  
**SAYS SO!**

The genocidal CCP, with help from Bill Gates and the compromised President of the United States, has allowed BGI-Group to amass Americans' DNA - what will they do next?

